Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
#stockmarket #breaking
Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial – CNBC
